Cirius's candidate drug MSDC-0602K showed positive results in stage 2b trial EMMINENCE for the treatment of NASH

recently, Cirius(http:// announcedthat its maindrug(http://MSDC-0602K, significantly improving patients' liver enzyme levels, blood sugar control, and insulin resistance in the phase 2btrial(http:// of patients treating non-alcoholic fatty hepatitis (NASH) patientsMSDC-0602K is a second-generation oral insulin sensitistCompared with the first generation, its design concept attempts to regulate the function of mitochondrial acetone acid carrier (MPC) at the same time, to minimize the direct excitatory effect of peroxidase proliferation activation receptor gamma (PPAR), while retaining the efficacy of the drug, with better safetyMSDC-0602K and MPC can selectively combine and regulate acetone acid into the mitochondriaMPC is a protein complex in the membrane of mitochondria that mediates the rate at which acetone acid enters the mitochondriaAcetone acid is an intermediate product of carbohydrate metabolism and is one of the important energy sources of cellsPreclinical studies have shown that regulating MPC can improve insulin resistance, fat metabolism and inflammatory effects402 NASH patients participated in the Phase 2b clinical trial called EMMINENCEThe results showed that three different doses of MSDC-0602K (62.3 mg, 125 mg, 250 mg) significantly lowered the patient's NAFLD activity score (NAS) by 33.3 percent, 39.8 percent and 42.6 percent of patients by at least 2 points compared to the baseline 　　Serum alanine amino metastase (ALT) and temporyaaminomety transferase (AST) levels also improved compared to the placebo group Of these, 20.8% and 33.3% of patients with ALT normalization levels in the 125 mg and 250 mg dose groups were 20.8% and 33.3%, respectively, compared with 6.8% in the placebo group 　　In addition, all MSDC-0602K dose groups showed a significant improvement in hbA1c levels, one of the markers for blood glucose control